tbuckley/cabot-search huggingface dataset:
1461P Predictive value of residual FDG-PET metabolic activity in metastatic non-small cell lung cancer (mNSCLC) patients (pts) with long-lasting response to immune checkpoint inhibitors (ICIs)
Authors: A-C. Toublanc, A. Crombe, R. Veillon, C. Domblides, M. Cabart, F. Chomy, M. Zysman, S. Cousin
Journal: Annals of Oncology (2023)
1460P GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)
Authors: F.D.A. Aparisi Aparisi, E. Felip, E. Pichon, E. Carcereny, P. Barre, R. Raumlau, T. Sethi, B. Lindmark, R. Slack, A. MacKinnon, V. Aslanis, D. Phung, P. Jensen, Z. Rajiwate, G. Ross, L. Basse, F. Ghiringhelli
Journal: Annals of Oncology (2023)
1456P Exploring biological and molecular factors as outcome predictors for pembrolizumab (Pem) or pembrolizumab-chemotherapy (Pem-CT) in advanced non-small cell lung cancer (NSCLC)
Authors: L. Zullo, M. Aldea, F. Paoloni, A. Rosa, V. Fontana, E. Cella, D. Soldato, M. Gualtieri, M.P. Spotti, G. Barletta, C. Dellepiane, G. Rossi, E. Bennicelli, M-L. Meyer, C. Parisi, L. Del Mastro, D. Planchard, R. Berardi, B. Besse, C. Genova
Journal: Annals of Oncology (2023)
1475P Torque teno virus DNA load as biomarker for tumor response to mono immune checkpoint inhibition in non-small cell lung cancer
Authors: B. Muntinghe, C. van Leer-Buter, P. Rozendal, E. Suazo Zepeda, H. Kievit, E.A.M. Verschuuren, H.J.M. Groen, A.J. Van Der Wekken, G.H. de Bock, E. Schuuring, J.T.J.N. Hiltermann
Journal: Annals of Oncology (2023)
1487P Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer: Updated results
Authors: Q. Wang, A. Xu, C. Ma, T. Wang, P. Liu, Y. Duan, T. Kong, G. Chen, X. Jia, K. Shang, G. Yang, G. Zhang, F. Yu, H. Wang, H. Chen
Journal: Annals of Oncology (2023)
1465P Clinical impact of proton pump inhibitor on the therapeutic outcome of non-small cell lung cancer patients with PD-L1 TPS ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor plus chemotherapy: A retrospective multicenter cohort study
Authors: H. Kawachi, T. Yamada, M. Tamiya, Y. Negi, Y. Goto, A. Nakao, S. Shiotsu, K. Tanimura, T. Takeda, A. Okada, T. Harada, K. Date, Y. Chihara, I. Hasegawa, N. Tamiya, M. Iwasaku, S. Tokuda, T. Kijima, K. Takayama
Journal: Annals of Oncology (2023)
1494P Fruquintinib combined with sintilimab and chemotherapy as the first-line treatment in advanced naive EGFR- and ALK-negative non-squamous non-small cell lung cancer(nsq-NSCLC): Updated results of a phase II trial
Authors: Y. Shu, P. Ma, H. Shen, W. Gao, X. Chen, J. Sun, L. Xu
Journal: Annals of Oncology (2023)
1639P Feasibility of tumor genomic sequencing on tissue obtained from endoscopic ultrasound in patients with pancreatic cancer
Authors: V. Florou, J. Smith, J. Morris, C. Ko, C.D. Nevala-Plagemann, K. Barber, L. Olson, H.P. Soares, I. Garrido-Laguna
Journal: Annals of Oncology (2023)
1477P STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
Authors: A. De Giglio, D. de Biase, A. Di Federico, T. Maloberti, C. Casadio, E. Gruppioni, A. Altimari, B. Melotti, F. Sperandi, F. Gelsomino, A. Ardizzoni
Journal: Annals of Oncology (2023)
1499P Wnt5-ROR2 signalling mediated resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
Authors: E. Giroux-Leprieur, P. Takam Kamga, M. Mayenga, A.E. Costantini, C.G. Kotokpo Youkou, C. Julie, C. Capron, M. Glorion, J-F. Emile
Journal: Annals of Oncology (2023)
1716P Addressing clinical trial disparities in Spain: A digital solution
Authors: M. Hardy-Werbin, J.J. Garcia Mosquera, S. González Gallardo, D. Lepke, T. Espinosa, A.M.D. Degrave, M. Sánchez Calleja, M. Szarfer Barenblit, A. Llopart Babot, E. Arriola
Journal: Annals of Oncology (2023)
1495P Cemiplimab plus chemotherapy versus chemotherapy in non-small cell lung cancer with PD-L1 ≥1%: EMPOWER-Lung 3 results
Authors: A. Baramidze, T. Makharadze, M. Gogishvili, T. Melkadze, D. Giorgadze, K.D. Penkov, K. Laktionov, G. Nemsadze, M. Nechaeva, I. Rozhkova, E. Kalinka, D. McIntyre, M. Kaul, R.G.W. Quek, J-F. Pouliot, F. Seebach, G. Gullo, P. Rietschel
Journal: Annals of Oncology (2023)
1469P The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer
Authors: J. Rogado, F. Pozo, K. Troule, M. Pacheco, M. Adrados, J.M. Sanchez Torres, F. Al-Shahrour, A. Alfranca, N. Romero Laorden, R. Colomer Bosch
Journal: Annals of Oncology (2023)
1496P Higher levels of CSF-1 support resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
Authors: P. Takam Kamga, M. Mayenga, L. Sebane, A.E. Costantini, C.G. Kotokpo Youkou, C. Julie, C. Capron, F. Parent, C. Guettier, A. Seferian, J-F. Emile, E. Giroux-Leprieur
Journal: Annals of Oncology (2023)
1450P Addition of bevacizumab to first-line chemoimmunotherapy in NSCLC with liver metastases
Authors: M. Roulleaux Dugage, M. Tagliamento, T. Gorria, A. Rochand, L-M. Garcin, S. Oudard, C. Thibault, V.M. Albarran Artahona, J.C. Laguna Montes, I. Nalda Ariza, F.J. Muñoz i Carrillo, L. Aguilar, A. Arcocha, L. Lupinacci, C. Teixido, B. Besse, L. Mezquita, E. Auclin
Journal: Annals of Oncology (2023)
1686TiP Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations
Authors: T. Macarulla, F. Castet, M. Lobo de Mena, R. Garcia-Carbonero, E. Martinez de Castro, A.J. Munoz Martin, R.A. Pazo Cid, B. Grana Suarez, J. Gallego Plazas, R. Alvarez, I.C. Ales Diaz, I. Gallego Jimenez, B. Laquente, M. Rodriguez, B. García Paredes, M.T. Cano Osuna, I. Ruiz de Mena, C. Fabregat-Franco, P. Espinosa Olarte, E. Aranda Aguilar
Journal: Annals of Oncology (2023)
1474P Outcome of nivolumab and ipilimumab-based therapy for advanced non-small cell lung cancer with low or negative PD-L1 expression
Authors: T. Fukui, S. Hori, Y. Hatakeyama, T. Kiriu, K. Matsumura, N. Miwa, M. Katsurada, K. Okuno, S. Yoshimura, M. Tachihara
Journal: Annals of Oncology (2023)
1467P Combination therapy of envafolimab and suvemcitug with chemotherapy in patients with non-small cell lung cancer (NSCLC): Results from a phase II clinical trial
Authors: C. Wu, L. Wu, X. Meng, Y. Wang, Q. Fan, X. Wang, K. Gu, R. Ma, C. Hu, L. Lu, F. Su, C. Yang, Z. Liu, J. Tian, X. Sun, S. Sun, Y. Cheng
Journal: Annals of Oncology (2023)
1485P Systemic inflammatory index dynamics at 6 weeks as an early surrogate for clinical benefit in patients with NSCLC and PD-L1≥50% expression treated with pembrolizumab: Data from the real-life practice
Authors: M. Knetki-Wroblewska, A. Piórek, S. Tabor, K. Winiarczyk, P. Sobczuk, Z. Lewandowska, A. Pluzanski, D.M. Kowalski, M.J. Krzakowski
Journal: Annals of Oncology (2023)
1659P The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials
Authors: O. Letissier, C. Smolenschi, A. Hollebecque, D. Vasseur, S. Champiat, R. Bahleda, A. Gazzah, J-M. Michot, F-X. Danlos, K. Ouali, C. Henon, L. Mahjoubi, V. Goldschmidt, Y. Loriot, C. Massard, A. Bayle, A. Italiano, C. Baldini, S. Ponce Aix
Journal: Annals of Oncology (2023)
1482P Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in elderly adults aged over 75 years
Authors: J. Sakakibara-Konishi, Y. Yamanaka, T. Kurata, K. Watanabe, Y. Hosomi, H. Horinouchi, Y. Ohe, Y. Nakahara, T. Asao, S. Saeki, Y. Tsubata, Y. Fujita, H. Mizugaki, M. Ohuchi, S. Yagishita, A. Hamada
Journal: Annals of Oncology (2023)
1493P A phase II, multi-center, open-label, dose-optimization study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Preliminary results
Authors: T. Jankowski, S. Sótér, R. Raumlau, N. Chilingirova, M.D. Cholakova, B. Seidl, M. Moore, R. Joshi, V. Vitoc, V. Zaporojan, S. Gryaznov, P. Watkins, M. Obrocea
Journal: Annals of Oncology (2023)
1501TiP A phase III global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met overexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01)
Authors: A. Lugini, J.W. Goldman, J. Tanizaki, H. Akamatsu, S. Xia, C. Ratajczak, M. Li, E. Bolotin, J. Seraj, S. Lu
Journal: Annals of Oncology (2023)
1683TiP Trial in progress: NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer-NEO-IMPACT
Authors: S. Maloney, N. Tebbutt, M. Nikfarjam, J. Samra, S. Mendis, J. Tie, L. Christopherson, S. Hayes, N. Berthon-Jones, C.H.H. Yim, E. El-Omar, L. Chantrill
Journal: Annals of Oncology (2023)
1500TiP REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design
Authors: E. Ghorani, M. Quartagno, F. Blackhall, D.C. Gilbert, M.E.R. O'Brien, C.H.H. Ottensmeier, E. Pizzo, J. Spicer, A. Williams, P. Badman, C. Milner-Watts, M.K. Parmar, M.J. Seckl
Journal: Annals of Oncology (2023)
1142P Personalized decision making in cutaneous squamous cell carcinoma: Integrating a clinico-pathological model for absolute metastatic risk into the staging systems
Authors: M. Wakkee, L. Pozza, H. van de Werken, A. Mooyaart, J. Dwarkasing, S. Alex, D. Bellomo, L. Zandwijk-Hollestein, B. Rentroia Pacheco
Journal: Annals of Oncology (2023)
1113P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma
Authors: D. Schadendorf, R. Dummer, K.T. Flaherty, C. Robert, A.M. Arance Fernandez, J.W. de Groot, C. Garbe, H. Gogas, R. Gutzmer, I. Krajsova, G. Liszkay, C. Loquai, M. Mandalà, N. Yamazaki, C.A. Guenzel, A. Polli, M. Thakur, A. di Pietro, P.A. Ascierto
Journal: Annals of Oncology (2023)
1123P Baseline tumor-infiltrating lymphocytes and response to immune checkpoint inhibition in advanced melanoma
Authors: M. Schuiveling, I. van Duin, L.S. ter Maat, F.W.P.J. Van den Berkmortel, M.J. Boers-Sonderen, J.W. de Groot, E. Kapiteijn, M. Labots, D. Piersma, A.M.R. Schrader, G. Vreugdenhil, H.M. Westgeest, J. Pluim, M. Veta, W.A. Blokx, P.J. van Diest, K.P.M. Suijkerbuijk
Journal: Annals of Oncology (2023)
1138P Intralesional administration of L19IL2/L19TNF in difficult-to-treat non-melanoma skin cancer shows a favorable safety profile and preliminary clinical activity
Authors: L. Flatz, U. Leiter-Stoppke, F. Meraz-Torres, F. Wolfsperger, A. Meiwes, N. Wagner, L. Nadal, E. Puca, G. Elia, A. Covelli, D. Neri, C. Antonio, T.M.S. Amaral
Journal: Annals of Oncology (2023)
1206O Clinical subtyping of cancer from blood based on comprehensive epigenomic profiling
Authors: S. Baca, J-H. Seo, J.E. Berchuck, T. El Zarif, R.M. Saliby, K. Semaan, B. Fortunato, M.M. Awad, C. Chau, J.A. DeCaprio, W.D. Figg, A. Hata, F.S. Hodi, K. Ligon, K. Ng, M. Oser, S.M. Tolaney, P. Wen, M. Freedman, T.K. Choueiri
Journal: Annals of Oncology (2023)
1114P Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002 - BECARE)
Authors: A. Soria, P. Sanchez Mauriño, R. García Galindo, S. Sequero, L. Gutiérrez Sanz, G. Crespo, R. Díaz-Beveridge, T. Puértolas, P. López, J. Fra Rodríguez, R. López Castro, C. Aguayo, J. Valdivia, A. Cunquero-Tomás, G. Benítez, P. Ayala de Miguel, E. Espinosa, E. Muñoz-Couselo, B. Campos, P. Cerezuela-Fuentes
Journal: Annals of Oncology (2023)
1145P Clinical characteristics and survival of patients with advanced Merkel cell carcinoma (MCC) treated with avelumab: Analysis of a prospective German MCC registry (MCC TRIM)
Authors: J.C. Becker, S. Mahmoudpour, D. Schadendorf, U. Leiter-Stoppke, F. Meier, R. Herbst, M. Sachse, S. Grabbe, C. Gebhardt, F. Ziller, C. Pfoehler, P. Mohr, L. Zimmer, E. Boutmy, S. Hoff, P. Verpillat, A. Fernandez Milano, M. Shlaen, C. Fu, S. Ugurel-Becker
Journal: Annals of Oncology (2023)
1146P Updated results from POD1UM-201: A phase II study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC)
Authors: G. Grignani, P. Rutkowski, C. Lebbe, M. Guida, C. Gaudy Marqueste, F.G.M. De Braud, F. Spagnolo, M. Burgess, H. Montaudie, R. Depenni, F. Spada, J. Pulini, M. Cornfeld, C. Tian, S. Bhatia
Journal: Annals of Oncology (2023)
1125P Identification of a subset of metastatic melanoma patients demonstrating germline determined insensitivity to immunotherapy
Authors: B.P. Fairfax, C. Taylor, R.A. Watson, W. Ye, O. Tong, F. Matos Santo, N.A. Coupe, M.R. Middleton, M. Payne
Journal: Annals of Oncology (2023)
1134P Safety and efficacy of low dose (LD) ipilimumab (Ipi) + pembrolizumab (pem) in checkpoint inhibitor (CPI) naïve patients (pts) with melanoma brain metastases (MBM)
Authors: I.C. Glitza, D. Milton, V. Honaker, S. Turner, T. Hennegan, T. Beckham, R. Amaria, S. Patel, A. Diab, M. Wong, J. Mcquade, C. Yee, M. Davies, E. Burton, H.A. Tawbi
Journal: Annals of Oncology (2023)
1117P Overall survival (OS) in patients with metastatic BRAF V600-mutant melanoma treated with encorafenib plus binimetinib (ENCO+BINI): Comparing real-world vs clinical trial data
Authors: G.K. In, K. Chen, G. Sajeev, R. Simpson, S. Kalia, D. Christensen, D. Liu, N. Rezai, A. di Pietro, J. Signorovitch
Journal: Annals of Oncology (2023)
1139P Final results of a phase II study of pembrolizumab as first-line treatment in advanced cutaneous squamous cell carcinomas (CSCCs)
Authors: E. Maubec, M. Boubaya, L. Deschamps, M. Beylot-Barry, P. Petrow, I. Scheer-Senyarich, N. Basset-Seguin, C. Gaudy Marqueste, G. Quereux, C. Bloch-Queyrat, M-T. Leccia, A. Stefan, P. Saiag, F. Grange, N. Meyer, S. Dalac Rat, C. Alloux, I. Lopez, A. Tibi, V. Levy
Journal: Annals of Oncology (2023)
1143P Changes in peripheral and local tumor immunity after cemiplimab treatment early describe clinical outcomes in patients with cutaneous squamous cell carcinoma
Authors: D. Esposito, A.R. Amato, C. Barraco, S. Belli, C.M. Ascione, A. Vallefuoco, F. Pepe, A. Servetto, R. Bianco, L. Formisano
Journal: Annals of Oncology (2023)
1128P A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma
Authors: S. Patel, M. Mckean, S. Piperno-Neumann, A.N. Shoushtari, L. Hernandez-Aya, M. Orloff, S. Khan, K. Montazeri, E. Kapiteijn, E. Buchbinder, S. Agresta, S. Reilly, C.M. Patriquin, D. Hickman, D. Corrigan, L. Granlund, M. Hentemann, J. Piel, P. Martin, I. Mehmi
Journal: Annals of Oncology (2023)
1124P IL-6 as prognostic factor in adjuvant or metastatic skin cancer patients treated with immunotherapy: A deep biomarker analysis
Authors: D. Mallardo, S. Arpino, M.G. Vitale, A. Minopoli, M. Tuffanelli, C. Trojaniello, M. Mallardo, M. Ottaviano, G. D'Angelo, V. Vanella, F. Sparano, E. Cioli, B. Alfano, L. Festino, A. Budillon, E. Simeone, C. Caracò, E. Cavalcanti, P.A. Ascierto
Journal: Annals of Oncology (2023)
1119P Stage IIIA melanoma with isolated tumor cells in lymph nodes: Time for reviewing the AJCC v8 classification
Authors: T.M.S. Amaral, L. Nanz, R. Stadler, A. Forschner, A. Meiwes, F. Meraz-torres, F. Wolfsperger, E. Chatziioannou, L. Flatz, C. Garbe, U. Leiter-Stoppke
Journal: Annals of Oncology (2023)
1157P Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival
Authors: R.J. Verheijden, J.C. Janssen, A.E. Putker, S.P.G.R. Veenstra, G.A.P. Hospers, M.J.B. Aarts, K.W. Hehenkamp, V.L.E. Doornebosch, M. Verhaert, F.W.P.J. Van den Berkmortel, F.H. Burgers, J.B.A.G. Haanen, D. Piersma, E. Kapiteijn, M. Labots, M.J. Boers-Sonderen, A.A.M. Van der Veldt, S. Aspeslagh, A.M. May, K.P.M. Suijkerbuijk
Journal: Annals of Oncology (2023)
1111P A randomised phase II study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)
Authors: A. Gupta, R.N. Matin, A. Dayimu, J. Nobes, R.E. Board, M. Payne, A.R. Rao, A. Fusi, S. Danson, B.K. Eccles, J. Carser, C. O'Hanlon Brown, N. Steven, G.J. Burghel, L. Demain, E.C. Baker, J. Wulff, S. Twelves, M.R. Middleton, P.G. Corrie
Journal: Annals of Oncology (2023)
1130P Tebentafusp (tebe) in an ongoing cohort of 72 French patients (pts) with metastatic uveal melanoma (mUM)
Authors: L. Mailly-Giacchetti, T. Ramtohul, S. Renault, M. Saint-Ghislain, M. Pracht, J-C. Thery, P-F. Combe, N. Litrowski, H. Martin, C. Dutriaux, L. De Koning, V. Servois, S. Piperno-Neumann, M.J. Rodrigues
Journal: Annals of Oncology (2023)
1140P Cemiplimab versus historical systemic treatments for locally advanced (la) or metastatic (m) cutaneous squamous cell carcinomas (CSCC): Results from the French study TOSCA
Authors: E. Gerard, C. Lebbe, E. Lanoy, G. Quereux, P. Bernard, M-A. Viguier, N. Meyer, L. Mortier, M. Dinulescu, D. Legoupil, E.M. Neidhardt, P. Saiag, S. Trabelsi-Messai, P. Celerier, C. Nardin, E. Maubec, E. Hainaut Wierzbicka, S. Perrier, S. Garnier, C. Robert
Journal: Annals of Oncology (2023)
1159P Characterization of melanoma of unknown primary in the era of immunotherapy and targeted therapy in Spain: Results from the prospective real-world study GEM 1801
Authors: P. Cerezuela-Fuentes, A. Piñero-Madrona, E. Muñoz-Couselo, J.L. Manzano, M-Á. Berciano-Guerrero, M. Majem, E. Espinosa, A. Soria, P. Ayala de Miguel, A. García Castaño, G. Crespo, L. Gutiérrez Sanz, C. Aguado de la Rosa, L.A. Fernández-Morales, T. Puértolas, J. Fra, M. Rodríguez de la Borbolla, L. Bellido, S. Martín Algarra, I. Márquez-Rodas
Journal: Annals of Oncology (2023)
1161P Therapeutic outcome of molecular profiling of melanoma patients resistant to standard treatment: Real-world data
Authors: M. Sakkal, M. Aldea, A. Bayle, D. Vasseur, E. Routier, D. Belkadi-Sadou, A. Marchand, A. Gazzah, C. Smolenschi, R. Bahleda, C. Baldini, S. Champiat, Y. Loriot, L. Lacroix, E. Rouleau, A. Hollebecque, A. Italiano, S. Ponce Aix, C. Robert
Journal: Annals of Oncology (2023)
1154P Thromboembolic events in patients with melanoma receiving immune checkpoint inhibitors: Incidence and risk factors
Authors: D. van Dorst, M.M. Hofman, R.M. de Waal, E. Oomen-de Hoop, K.D. Joode, S. Bins, S.L. Koolen, A. Joosse, J. Versmissen, A.A.M. Van der Veldt, R.H. Mathijssen
Journal: Annals of Oncology (2023)
1148P Avelumab as second-line or later (2L+) treatment (tx) in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Real-world tx patterns in France
Authors: A. Blom Fily, L. Mortier, B. Van Hille, M. Samimi, L. Luciani, C. Cahuzac, C. Robert, G. Quereux, E. Maubec, C. Maillard, H. Miotti, F. Aubin, C. Lenormand, M-N. Solbes, A.B. Duval Modeste, I. Kachaner, C. Lebbe, C. Dutriaux, P. Saiag
Journal: Annals of Oncology (2023)
1112P Five-year survival after intermittent targeted therapy and anti-PD1 in stage IV melanoma: An update of the IMPemBra trial
Authors: L. Hoeijmakers, E.A. Rozeman, M. Lopez-Yurda, L. Grijpink-Ongering, B. Heeres, B. van de Wiel, C. Flohil, A. Sari, S. Heijmink, D. Van Den Broek, A. Broeks, J.W. de Groot, M. Vollebergh, S. Wilgenhof, H.V. van Thienen, J.B.A.G. Haanen, C.U. Blank
Journal: Annals of Oncology (2023)
1135P Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 204
Authors: R. Huang, G. Youssef, T. Nelson, P. Wen, P. Forsyth, F.S. Hodi, K.A. Margolin, A.P. Algazi, O. Hamid, C.D. Lao, M.S. Ernstoff, S.J. Moschos, M.B. Atkins, M. Postow, D.A. Reardon, D.J. Grootendorst, M. Askelson, C. Ritchings, H.A. Tawbi
Journal: Annals of Oncology (2023)
1147P First-line treatment (tx) patterns and overall survival (OS) of patients (pts) with advanced Merkel cell carcinoma (aMCC) in England from 2013-2022: Results of a nationwide observational cohort study
Authors: C. Knott, S. Mahmoudpour, M. Kearney, E. Boutmy, P. Verpillat
Journal: Annals of Oncology (2023)
1115P Comparison of efficacy and toxicity of dabrafenib/trametinib versus vemurafenib/cobimetinib therapy in routine medical practice: Eight years of BRAF/MEK inhibitor use in routine clinical practice
Authors: K. Piejko, B. Cybulska-Stopa, A.M. Czarnecka, K. Ostaszewski, M. Ziętek, L. Galus, W. Bal, T. Kubiatowski, G. Kaminska-Winciorek, R. Suwinski, J. Mackiewicz, R. Dziura, E. Rutkowska, T. Switaj, P. Rogala, N. Kempa-Kaminska, P. Blonski, M.K. Zielińska, P. Rutkowski
Journal: Annals of Oncology (2023)
1126P REtrospective Study of definitive therapy for head and neck mUcosal MElanoma: The RESUME study
Authors: M. Nomura, N. Kiyota, Y. Shimizu, A. Motegi, T. Akimoto, T. Mukaigawa, T. Fujii, N. Tsushima, K. Shiga, T. Koyama, D. Kawakita, A. Ohkoshi, M. Nakahira, N. Hanai, S. Murono, T. Ueda, H. Mitani, A. Homma
Journal: Annals of Oncology (2023)
1160P Methods of nivolumab administration in advanced melanoma: A comparison of patients’ clinical outcomes treated with flat dose or weight-adjusted dose, FLATIMEL study
Authors: I. Campo le Brun, S. Dalle, L. Mortier, O. Dereure, S. Dalac Rat, C. Dutriaux, M-T. Leccia, D. Legoupil, H. Montaudie, J. De Quatrebarbes, C. Gaudy Marqueste, E. Maubec, P. Saiag, C. Pages, F. Brunet Possenti, F. Granel Brocard, R. Porcher, W. Lefevre, C. Lebbe, E. Kempf
Journal: Annals of Oncology (2023)
1122P Neutrophil/lymphocyte ratio and systemic inflammatory index as prognostic biomarkers in metastatic melanoma patients under immune checkpoint inhibitors: Could any of them be used?
Authors: M.B. Menezes, L. Goncalves, I.Q. Dunões, P. Semedo, S.L. Lobo Martins, A.G. da Silva Oliveira, G.M. Baió, C. Alvim, I.S. Soares de Pinho, T. Barroso, V.D.C. Patel, M. Esperanca-Martins, R.L. Brás, A.R. Teixeira Sousa, A.B. Mansinho, S. Torres, M.M. Inácio, L. Costa, R.D. Dinis
Journal: Annals of Oncology (2023)
1144P High-plex spatial profiling of cutaneous squamous cell carcinoma to identify biomarkers associated with clinical outcomes: The cMIC study
Authors: R. Ladwa, J. Monkman, H. Sadeghirad, C. Cooper, G. Belz, J. Bowman, H. Schaider, H. Liu, A. Kulasinghe, S. Porceddu
Journal: Annals of Oncology (2023)
1109P Second-line pembrolizumab (pembro) in Chinese patients (pts) with advanced melanoma: Long-term follow-up of the phase I KEYNOTE-151 study
Authors: L. Si, X. Zhang, Y. Shu, H. Pan, D. Wu, J. Liu, L. Mao, X. Wang, X. Wen, Y. Gu, L. Zhu, S. Lan, X. Cai, S. Diede, S.S. Chen, H. Hu, J. Guo
Journal: Annals of Oncology (2023)
1133P SF3B1 mutation predicts improved overall survival in metastatic uveal melanoma patients: Molecular and clinical correlates
Authors: L.P. del Carpio Huerta, M. Varela, M. Goma, E. Purqueras, D. Lorenzo, C. Gutierrez, A. Slocker, J. Caminal, J.M. Piulats Rodriguez
Journal: Annals of Oncology (2023)
1120P Development and external validation of a clinical prediction model to predict recurrence-free survival and melanoma-specific survival in patients with melanoma after sentinel lymph node biopsy
Authors: R.C. Stassen, C. Maas, A.A.M. Van der Veldt, S. Lo, R. Saw, A. Varey, R. Scolyer, G.V. Long, J. Thompson, P. Rutkowski, U. Keilholz, A.C.J. van Akkooi, C. Verhoef, D. van Klaveren, D. Gruenhagen
Journal: Annals of Oncology (2023)
1155P Application of novel machine learning to predict immunotherapy related toxicities for metastatic melanoma patients from baseline 18F-FDG PET/CT scans
Authors: R.J. Francis, M. Dell'Oro, E.S. Gray, D. Huff, T.G. Perk, R. Munian-Govindan, M.A. Ebert, M. Millward
Journal: Annals of Oncology (2023)
1156P Immune-related adverse events in a nationwide cohort of melanoma patients treated with adjuvant anti-PD1: Seasonal variation and association with outcome
Authors: E. Ellebæk, R.S. Jurlander, L.M. Guldbrandt, R.B. Holmstroem, M. Donia, C.A. Haslund, H. Schmidt, L. Bastholt, C.H. Ruhlmann, I-M. Svane
Journal: Annals of Oncology (2023)
1107P BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma
Authors: A.N. Shoushtari, M.R. Middleton, O. Hamid, F. Meier, T. Bauer, A.K.S. Salama, J.M. Kirkwood, P.A. Ascierto, P. Lorigan, C. Mauch, M. Orloff, R. Edukulla, H. Goodall, J.C. Hassel, T.R.J. Evans
Journal: Annals of Oncology (2023)